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Abstract Prostate cancer is the second most diagnosed
cancer in males in the world. Plasma quantification of
prostate-specific antigen substantially improved the early
detection of prostate cancer, but still lacks the required
specificity. Clinical management of prostate cancer needs
advances in the development of new non-invasive
biomarkers, ameliorating current diagnosis and prognosis
and guiding therapeutic decisions. microRNAs (miRNAs)
are a class of small non-coding RNAs that regulate gene
expression at the post-transcriptional level. These miRNAs
are expressed in the cells and are also present in cell-
derived extracellular vesicles such as exosomes. Exosomes
have been shown to act as mediators for cell to cell com-
munication because of the regulatory functions of their
content. High levels of exosomes are found in several body
fluids from cancer patients and could be a potential source
of non-invasive biomarkers. In this review, we summarize
the diagnostic and prognostic utility of exosomal miRNAs
in prostate cancer.
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Prostate cancer
Prostate cancer is the most commonly diagnosed male
malignancy and the second leading cause of cancer-related
death in males in the western world [1, 2]. Malignant
transformation of prostate epithelial cells and progression
to carcinoma are likely to result from a complex series of
events under both genetic and environmental influences
[3, 4]. Prostate cancer develops mainly in aged men, the
inherited risk of prostate cancer is as high as 60% [5] and
some predisposing genes have been identified [6–8]. Other
risk factors include race, a diet rich in fat, and obesity [3].
A better understanding of the genetic and biologic mech-
anisms that determine why some prostate carcinomas
remain silent while others cause serious, even life-threat-
ening illness are needed [5].
In the early stages, the disease locally confined to the
prostate, is hormone or androgen-dependent and can be
managed by surgical intervention or radiation treatment
[4]. In the case of advanced prostate cancer, androgen
deprivation therapy initially reduce tumor burden and cir-
culating prostate-specific antigen (PSA), but unfortunately
the disease relapse in most cases [9]. Advanced prostate
cancer can present metastasis in the lung, pleura, liver and
bone, with a great impact in patient morbidity and
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mortality despite aggressive therapy [10]. Currently,
prognostic markers are serum levels of PSA, Gleason score
and pathological stage [11]. PSA is secreted by prostate
cancer cells and can be found in blood, but has a low
specificity as biomarker because its level can also be ele-
vated for non-cancerous reasons [12, 13] or even dimin-
ished in metastatic disease [14]. These tests do not
distinguish exactly the aggressiveness of the tumor or the
potential metastatic capacity, so prostate biopsy, an inva-
sive procedure, remains the only definitive diagnostic test
for prostate cancer. But the implementation of novel state-
of-the-art techniques such as the analysis of exosomal
content of microRNAs (miRNAs) might be a promising
candidate for the diagnosis and disease stratification of
prostate cancer.
miRNA biogenesis, functions and implications
in cancer
miRNAs are endogenous, small, from 18 to 25 nucleotides
and non-coding RNAs widely found in both animals and
plants that regulate post-transcriptionally gene expression.
These small RNAs down-regulate gene expression by
binding a region in the 30 untranslated region (30UTR) of
their messenger RNA (mRNA) targets [15–17]. If the
miRNA completely binds the sequence of their mRNA, the
mRNA degradation is induced, while by contrast when
miRNA bind incompletely, translational repression is
induced [18]. miRNAs genes are transcribed by RNA
polymerase II into long primary miRNAs (pri-miRNAs).
These pri-miRNAs are processed in the nucleus into 70–80
nucleotide precursor miRNAs (pre-miRNAs) by the RNase
III enzyme Drosha [19] and its cofactor DGCR8. Then pre-
miRNA is actively transported from the nucleus to the
cytoplasm by Exportin 5/Ran-GTP complex where is pro-
cessed by the enzyme Dicer in the cytoplasm. Dicer is an
RNase III endonuclease that cleaves the pre-miRNA into
the mature miRNA that become stably associated with the
RNA-induced silenced complex (RISC), forming the
miRISC. The miRISC inhibits the target genes by
repressing translation initiation, inducing deadenylation of
mRNA, and thereby inducing ribosomes to drop off pre-
maturely and promoting mRNA degradation by Argonaute,
one of its essential catalytic components [20] (Fig. 1).
miRNAs can target hundreds of transcripts, and more than
one miRNA can converge on a single target transcript, thus
the potential regulatory scenario of miRNAs is enormous.
In this regard, miRNAs expression profiles have been
found to be tissue type-specific and play important regu-
latory roles in a variety of biological process, such as cell
proliferation, intercellular signaling, cell growth, cell
death, cellular differentiation, apoptosis and metabolism
control [21]. miRNA expression in tumor has been found to
be up or down-regulated compared with normal tissue
supporting their complex dual role either as oncogene
(oncomir) or tumor suppressor gene [22]. For instance
miRNA-125b has been shown to be an oncomir in prostate
cancer but can also act as a tumor suppressor in ovarian and
breast cancer [23]. Not only miRNAs are deregulated in
cancer but also the enzymes involved in their biogenesis
and processing. For example, Dicer is up-regulated during
prostate cancer progression and its levels correlate with
clinical stage, lymph node status and Gleason score [24].
miRNAs can be detected in a small volume samples from
most body fluids, including serum, plasma, urine, saliva
and are known to circulate in a highly stable cell free form
[25]. Their stability, ease detection using a range of tech-
niques, including miRNA cloning, microarray, quantitative
PCR and next generation sequencing, make it feasible to
identify and confirm abnormal miRNA expression in most
human malignances [26]. These characteristics, together
with its association with neoplastic disease progression,
make miRNA an ideal tumor biomarker either in the tissue
or in body fluids [20].
Exosomes and prostasomes
Exosomes are nano-sized (40–100 nm) extracellular vesi-
cles (EV) derived from multivesicular bodies (MVB). Cells
use exosomes to exchange of proteins, lipids and nucleic
acids [27], therefore are important mediator for cell to cell
communication, and indeed are considered to play a fun-
damental role in many physiological and pathological
processes [28]. Exosomes are either released from normal
or neoplastic cells and are present in the blood plasma,
amniotic fluids, malignant ascites [29], breast milk [30] and
other body fluids such as urine [31]. Exosomes contain
mRNA, miRNAs and DNA so the transfer of this sort of
information and oncogenic signaling to the tumor
microenvironment let the modulation of tumor progression,
proliferation angiogenic switch, the formation of the
metastatic niche [32] and even the suppression of immune
responses [33] (Fig. 2).
Several molecules or pathways are involved in the
biogenesis of MVBs, such as the ESCRT machinery (en-
dosomal sorting complexes required for transport), certain
lipids (such as ceramide) and the tetraspanins [34]. MVBs
can be either fused with lysosomes or with the plasma
membrane, which allows the release of their content to the
extracellular compartment [35]. Exosomes then will inter-
act with recipient target cells via different mechanisms
such as plasma membrane fusion and transport (RAB11,
RAB27 and RAB35) or adhesion to corresponding recep-
tors [36, 37]. Unfortunately, the mechanism that regulates
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the exosomes release and uptake is still unknown. There
are different ways to isolate exosomes either from tissue
culture or form body fluids as sucrose density-gradient,
ultracentrifugation [38] or by means of antibodies against
exosomal markers, such as CD9, CD81, CD63 [39].
Recently, nanomembrane ultrafiltration concentrator and
ExoQuick reagent are used as an effective and proven
alternative to ultracentrifugation as well as a modified
exosome precipitation method offers also a quick and
scalable for exosomes isolation [40].
EVs, matching in size to vesicles from the prostate
epithelium, now are known as prostasomes, found inside
the ‘storage vesicles’ within prostate epithelial cells [41].
Prostasomes are microvesicles (50–500 nm) present in
prostate secretions, produced by prostatic ductal epithelial
cells and normal component of seminal fluid [42].
In prostasomes term, there are several populations: one
with a small size type equivalent to exosomes, and released
by prostate cells because of multivesicular endosomes with
the plasma membrane, and other type equivalent to
microvesicles with large size and derived by direct shed-
ding of plasma membrane [43].
Prostasomes play a role as antioxidant factors in semen
by interacting with polymorphonuclear neutrophils and
inhibiting NADPH oxidase activity, and thus can act as
antibacterial agents [44]. Interesting component have
similarly been found in prostasomes isolated from human
semen, such as prostatic acid phosphatase (PAP), PSA,
prostate-specific transglutaminase and prostate stem cell
antigen (PSCA) which are also markers for prostate
cancer [45]. Prostasome have also a peculiar lipid com-
position with high levels of sphingomyelin, cholesterol,
and glycosphingolipids [46] and in addition have also
been reported to contain chromosomal DNA, mRNA and
miRNA [47]. The protein content on prostasome surface
is also very relevant as the presence of complement
inhibitory proteins such as CD46 and CD59 that confer
resistance to complement dependent cytotoxicity [48].
Prostasomes are not only secret by normal prostatic cells
but also by neoplastic cells that export prostasomes to the
extracellular environment, participating in tumor prolif-
eration and metastasis [49]. Prostasome levels are
reportedly increased in prostate cancer patients and these
levels are associated with the disease aggressiveness [50].
The development of future isolation techniques for
prostasomes found in biological fluids will let to get
better insight in the identification and analysis of the
protein, lipid and nucleic acids content of them and the
potential utility for the diagnosis and prognosis of prostate
cancer.
Fig. 1 miRNA biogenesis and mechanism of action
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Exosomal miRNAs in prostate cancer
miRNAs are expressed not only in cells and present in
biological fluids, but can be found also in cell-derived
extracellular vesicles such as exosomes [51]. In fact, RNA
sequencing analysis of plasma-derived exosomes revealed
that miRNAs are the most abundant exosomal RNA species
[52]. The miRNA content of extracellular vesicles reflects
the miRNA expression profile of the cells they originated
from [53]. For example, Brase et al. screened more 60
exosomal miRNAs identifying mir-375 and mir-141 as
appropriate markers for prostate cancer [54]. This miRNAs
content in exosomes could be considered as a potential
novel biomarker for prostate cancer that may be used to
diagnose but also to predict the disease stage [55, 56]. This
is currently needed because the blood level of the gold
standard marker for prostate cancer, PSA, do not always
correlate with disease stage and aggressiveness of the
malignancy [57]. For example, miR-21 is significantly
elevated in the early stage, but not in advanced prostate
cancer [58] and miR-16 is up-regulated in plasma of
metastatic prostate cancer patients, but down-regulated in
primary or metastatic prostate cancer tissues [59]. Addi-
tionally, other miRNAs have been reported to be detected
in blood exosomes in metastatic prostate cancer patients
[60–63]. MiRNAs have identified deregulated in plasma
and serum microvesicles in prostate cancer patients com-
pared with healthy control [64] and were also associated
with the stage of the disease, the Gleason score and lymph
node metastasis. For instance, Lodes et al. found 15 miR-
NAs (miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p,
-486-5p, -92b, -574-3p, -636, -640, -766, -885-5p) over-
expressed in serum from stage 3 and 4 prostate cancer
patients compared with healthy controls [65]. Further-
more, Mahn et al., found miR-26a, miR-195, and let-7i to
be up-regulated in patients with prostate cancer compared
with patients affected by benign prostatic hyperplasia [66].
Therefore, the different expression of specific miRNAs in
liquid biopsies might be useful for a correct diagnosis.
Another source where to investigate neoplastic abnormal-
ities in prostate cancer with clinical value is the urine as its
composition reflects the alterations in urogenital system
[67].
An investigation of the proteome of urinary exosomes
identified 246 proteins differentially expressed in prostate
cancer patients compared to healthy male controls being
the majority of these proteins up-regulated in exosomes
from prostate cancer patients with high sensitivity and
specificity [68]. A urinary 3-gene expression assay in
exosomes has demonstrated an improved identification of
patients with higher-grade prostate cancer among men with
elevated PSA reduce the number of unnecessary biopsies
Fig. 2 Exosomes promote cell–cell communication playing an important role in gene regulation due to their ability to transport cancer-
promoting material such as miRNAs
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[69]. In a proof-of-concept study analyzing the transcrip-
tome in tumor exosomes isolated from the urine of patients
with prostate cancer, revealed biomarkers, with potential
for monitoring cancer patients. If it could expand to include
not only mRNAs but also miRNAs it will help to classify
the tumor phenotype, its severity and the tumor response to
treatment [70]. Additional studies have demonstrated
alteration of certain specifics miRNAs, such as mir-107,
mir-574-3p and mir-483-5p, found in the urine of men with
prostate cancer compared with healthy controls [70]. In
metastatic prostate cancer, miR-141 is enriched in exo-
somes found in cells obtained by urine sediments, as well
as in parallel tissue samples, suggesting the diagnostic and
prognostic potential of miR-141 for prostate cancer [71].
As shown in Table 1, there are several deregulated miR-
NAs in different liquid biopsy (serum, plasma, urine, saliva
and cells) of prostate cancer. Regarding other important
factors, it has been observed that the miRNAs content of
exosomes plays a role in docetaxel resistance. mir-34a that
was significantly decreased in prostate cancer versus nor-
mal tissues as well as in urine, regulates BCL-2 and may in
part, regulate the response to docetaxel [76, 77].
Conclusion
There is still limited knowledge about the biological roles
of exosomal miRNAs in prostate cancer. The development
of new exosome isolations methods and the incorporation
of high-throughput technologies as next generation
sequencing (NGS) for miRNA analysis will change dra-
matically the scenario. The scientific community will
advance in the use of plasma or urine exosomal miRNAs as
source for new prostate cancer biomarkers substituting
progressively invasive procedures as biopsy or serum PSA.
This challenge of blood-based assays may represent the
needed association between basic and clinical research,
driving definitively the outbreak of personalized medicine
in prostate cancer.
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Table 1 miRNAs deregulated in prostate cancer compared to healthy controls
MiRNAs deregulated in prostate cancer Source Potential target genes References
Let-7i, mir-16, mir-24, mir-26a, mir-26b, mir-34b,
mir-92b, mir-93, mir-103, mir-106a, mir-141, mir-
195, mir-197, mir-223, mir-298, mir-328, mir-346,
mir-375, mir-1290
Serum MAPK, p53, WNT5A EZH2,LARP1,AKT,
SOX2,PDCD10,SPAG9,SOCS5, MBNL1, MTPN,
E2F2, MYC, MCM7, BCL2, PLAG1, ACSL3,
HMGA1, EGF2, BCOX1, AKT,ITGA3/
ITGB1,p21
Hessvik et al. [61],
Moltzahn et al.
[72], Lodes et al.
[73]
Let-7e, let-7c, mir-20a, mir-21, mir-30c, mir-130b,
mir-145, mir-1811a-2*, mir-221, mir-301a, mir-
326, mir331-3p, mir-432, mir-574-3p, mir-622,
mir-625*, mir-1285, mir-2110, mir-141, mir-1290
Plasma HMGA2, IGF1R, AR, ABL2, PDCD4, TGFb,
BCL9, MMP2, SOX2, SENP1, Bmi1, SIRT1,
IRF2, RAB1A, HECTD2, NDRG2, DOHH,
ERBB-2, WNT5A, EZH2, LARP1
Shen et al. [74],
Huang et al. [52]
mir-107, mir-574-3p, mir-141-5p, mir-21-5p, mir-
34a, mir-483-5p
Urine WNT5A, EZH2, LARP1, PDCD4, p57Kip2, SIRT1,
CD44, WNT/TCF7, AR, Notch-1, c-Myc
Nina Pettersen
Hessvik et al. [61],
Samsonov et al.
[71]
mir-141, mir-21 Saliva MAPK, WNT5A, EZH2, LARP1, PDCD4,
FBXO11, p57Kip2, TGFBR2, MARCKS
Hizir et al. [58]
mir-141,mir-9, mir-200b,mir-21,mir-221,mir-
16,mir-92a, mir-103,mir-107, mir-197, mir-
92b,mir-574-3p,mir-885-5p,mir-298,mir-26a,mir-
1274a,mir-106a,mir-26b,mir-30b,c,d, mir-24, let-
7a,c,e,i, miR-1285,mir-20a,mir-107,mir-130b,mir-
301a,mir-331-3p,mir-625,mir-485-3p,mir-
874,mir-155,mir-181a-2, mir-326, mir-762, mir-
185, mir-151 and mir-149
Metastatic
cell line
(PC3)
IGFR1, TCR, GH, STAT, MAPK, PRLR, TGFb,
BCL2, ERG, PDGF-D, Bmi, TGFBR2, p57kip2,
MARCKS, Bmi, SIRT1, IRF2, SOCS3, HECTD2,
RAB14, DVL2, PDCD10, PI3 K, AKT3,
WNT5A, ULK2, BCL9, CDKN1B/p27, E2F2,
CCND2, AR, ABL2, CX43, MMP2, NDRG2,
DOHH, ERBB-2, ANXA7, DAX1, SREBP,
CASZ1, IL1RAPL1, SOX17, N4BP1, ARHGDIA
Hessvik et al. [75],
Alireza Ahadi et al.
[51]
Let-7a, b,c, mir-149, mir-762, mir-30b-3p, mir-
20a,b, mir-17-5p, mir-18a-5p, mir-106-5p, mir-93-
5p,
Metastatic
cell line
(VCaP)
KRAS, E2F2, CCND2, IGF1R, RPS2, AR, c-MYC,
ABL2, CX43, TIMP3, p300/CBP, RE-1, KEGG
Alireza Ahadi et al.
[51]
Let-7a, b,c,d,e,i, mir-17, mir-18a, mir-20a, mir-93,
mir-106b, mir-149
Metastatic
cell line
(LNCaP)
KRAS, E2F2, CCND2, IGF1R, RPS2, AR, c-MYC,
BPX3, ABL2, CX43, TIMP3, p300/CBP, RE-1,
PTEN, ZBTB4, p21, CASP7, SDC-1
Alireza Ahadi et al.
[51]
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